Related Experiment Video
Updated: Jun 28, 2026
09:26
In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function
Published on: October 16, 2013
In vitro evaluation of experimental agents for anti-HIV activity.
D D Richman1, V A Johnson, D M Mayers
1University of California, San Diego, La Jolla, California, USA.
Current Protocols in Immunology
|April 25, 2008
Summary
This study details a human immunodeficiency virus (HIV) cytopathic effect inhibition assay for screening antiviral drugs. The assay uses sensitive T cell lines to measure drug effectiveness by calculating the 50% inhibitory concentration (IC50).
Area of Science:
- Virology
- Immunology
- Drug Discovery
Background:
- Human immunodeficiency virus (HIV) infection remains a significant global health challenge.
- Developing effective antiviral therapies requires robust screening assays.
- Assessing drug efficacy involves measuring inhibition of viral replication and cytopathic effects.
Purpose of the Study:
- To present a reliable HIV cytopathic effect (CPE) inhibition assay for initial screening of antiviral agents.
- To describe methods for assessing anti-HIV activity by measuring syncytium formation and p24 gag protein production.
- To outline the calculation of the 50% inhibitory concentration (IC50) for candidate drugs.
Main Methods:
- Utilizing immortalized T cell lines (ATH8, MT2) highly sensitive to HIV-induced cytopathic effects.
- Performing inhibition assays to quantify the reduction in HIV-induced cell damage.
- Employing ELISA to measure inhibition of syncytium formation and p24 gag protein production.
- Calculating the 50% inhibitory concentration (IC50) to determine drug potency.
Main Results:
- The described HIV CPE inhibition assay serves as an effective initial screening tool.
- The methods allow for quantitative assessment of anti-HIV activity.
- The IC50 calculation provides a standard metric for drug efficacy.
Conclusions:
- The presented assay is valuable for the early-stage screening of potential HIV therapeutics.
- The combination of CPE inhibition, syncytium, and p24 assays offers a comprehensive approach to evaluating anti-HIV agents.
- Standardized calculation of IC50 facilitates drug comparison and development.
